A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

131

Participants

Timeline

Start Date

October 26, 2023

Primary Completion Date

July 8, 2025

Study Completion Date

July 1, 2026

Conditions
Thyroid Eye DiseaseTED
Interventions
DRUG

Satralizumab

Satralizumab will be administered by SC injection.

DRUG

Placebo

Placebo will be administered by SC injection

Trial Locations (46)

1090

Medizinische Universität Wien, Vienna

1133

Budapest Retina Associates Kft., Budapest

2000

Sydney Eye Hospital, Sydney

3002

Centre For Eye Research Australia, East Melbourne

5000

Royal Adelaide Hospital, Adelaide

11021

'Northwell Health Physician Partners Ophthalmology, Great Neck

13353

Charité-Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin

21100

Ospedale Di Circolo E Fondazione Macchi, Varese

21205

Johns Hopkins University, Baltimore

26506

WVU Eye Institute, Morgantown

45147

Universitätsklinikum Essen, Essen

48105

University of Michigan, Kellogg Eye Center, Ann Arbor

48149

Universitätsklinikum Münster, Münster

49085

Great Lakes Eye Care, Saint Joseph

56124

Azienda Ospedaliero Universitaria Pisana, Pisa

67206

Grene Vision Group, LLC, Wichita

72076

Universitäts-Augenklinik Tübingen, Tübingen

79106

Universitätsklinikum Freiburg, Klinik für Augenheilkunde, Freiburg im Breisgau

80131

A.O. U. Federico II, Napoli

84102

Eyelid Center of Utah, Salt Lake City

90210

Thrive Health Research LLC, Beverly Hills

97225

EyeHealth Northwest, Portland

119074

National University Hospital, Singapore

168751

Singapore Eye Research Institute, Singapore

92093-0946

UCSD Shiley Eye Center, La Jolla

78705-1169

Austin Retina Associates, Austin

C1425

Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada, Buenos Aires

C1015ABO

Centro Oftalmológico Dr. Charles S.A., Capital Federal

C1120AAN

Oftalmos, Capital Federal

C1061AAE

Buenos Aires Mácula, Ciudad Autonoma Buenos Aires

M5500BWG

Centrovision Mendoza, Mendoza

S2000DLA

Grupo Laser Vision, Rosario

01307

Universitätsklinikum Carl Gustav Carus, Klinik und Poliklinik für Augenheilkunde, Dresden

Unknown

Hong Kong Eye Hospital, Mong Kok

Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan

00168

Fondazione Policlinico Universitario A Gemelli, Rome

480-1195

Aichi Medical University Hospital, Aichi

812-8582

Kyushu University Hospital, Fukuoka

830-8577

Social Medical Corporation Tenjinkai Shinkoga Hospital, Fukuoka

060-8648

Hokkaido University Hospital, Hokkaido

657-0068

Kobe Kaisei Hospital Medical foundation, Hyōgo

807-8556

Hospital of the University of Occupational and Environmental Health,Japan, Kitakyushu-shi

612-8555

National Hospital Organization Kyoto Medical Center, Kyoto

889-1692

University of Miyazaki Hospital, Miyazaki

545-8586

Osaka Metropolitan University Hospital, Osaka

150-0001

Olympia Eye Hospital, Tokyo

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT05987423 - A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease | Biotech Hunter | Biotech Hunter